Why living cells matter in wound healing
Dr. Geoffrey Gurtner
Understanding wound care RCT’s and Clinical Data
Human Skin Allograft Murine Study
TheraSkin Re-Application Parameters & Examples
Dr. Adam Landsman
SonicOne and TheraSkin – The 1-2 Punch for Wound Healing
Dr. John Zboinski
Treating Challenging Mohs Defects
Dr. Stanislav Tolkachjov & Dr. Arti Masturzo
Mental Stamina during Challenging Times
Coleman Ruiz (former Navy Seal) & Dr. Arti Masturzo
New Real World Studies in TheraSkin Allograft for treating wounds
Protecting the Healthcare Provider in the workplace during the COVID-19 Pandemic
Dr. Richard P Goodman & Dr. Arti Masturzo
Matched-cohort study comparing bioactive human split-thickness skin allograft plus standard of care to standard of care alone in the treatment of diabetic ulcers: A retrospective analysis across 470 institutions.
A retrospective matched-cohort study of 3994 lower extremity wounds of multiple etiologies across 644 institutions comparing a bioactive human skin allograft, TheraSkin, plus standard of care, to standard of care alone.
Randomized, Prospective, Blinded-Enrollment, Head-To-Head Venous Leg Ulcer Healing Trial Comparing Living, Bioengineered Skin Graft Substitute (Apligraf) with Living, Cryopreserved, Human Skin Allograft (TheraSkin).
A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft.
A prospective comparison of diabetic foot ulcers treated with either a cryopreserved skin allograft or a bioengineered skin substitute.
A retrospective clinical study of 188 consecutive patients to examine the effectiveness of a biologically active cryopreserved human skin allograft (TheraSkin®) on the treatment of diabetic foot ulcers and venous leg ulcers.